|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0015520,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0032659,
umls-concept:C0205164,
umls-concept:C0439851,
umls-concept:C0442027,
umls-concept:C0851347,
umls-concept:C1552596,
umls-concept:C1555794,
umls-concept:C1947931
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-29
|
|
pubmed:abstractText |
There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. This analysis was performed to characterize the population pharmacokinetics and pharmacodynamics of rivaroxaban in patients participating in two phase II, double-blind, randomized, active-comparator-controlled studies of twice-daily rivaroxaban for the prevention of venous thromboembolism after total hip- or knee-replacement surgery.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0312-5963
|
|
pubmed:author |
pubmed-author:BauerKenneth AKA,
pubmed-author:BorrisLarsL,
pubmed-author:DahlOla EOE,
pubmed-author:ErikssonBengt IBI,
pubmed-author:FisherWilliam DWD,
pubmed-author:GentMichaelM,
pubmed-author:HaasSylviaS,
pubmed-author:HuismanMenno VMV,
pubmed-author:KäleboPeterP,
pubmed-author:KakkarAjay KAK,
pubmed-author:KwongLouis MLM,
pubmed-author:MisselwitzFrankF,
pubmed-author:MueckWolfgangW,
pubmed-author:TurpieAlexander G GAG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
203-16
|
|
pubmed:dateRevised |
2009-2-10
|
|
pubmed:meshHeading |
pubmed-meshheading:18307374-Adult,
pubmed-meshheading:18307374-Age Factors,
pubmed-meshheading:18307374-Aged,
pubmed-meshheading:18307374-Aged, 80 and over,
pubmed-meshheading:18307374-Arthroplasty, Replacement, Hip,
pubmed-meshheading:18307374-Arthroplasty, Replacement, Knee,
pubmed-meshheading:18307374-Dose-Response Relationship, Drug,
pubmed-meshheading:18307374-Double-Blind Method,
pubmed-meshheading:18307374-Factor Xa,
pubmed-meshheading:18307374-Female,
pubmed-meshheading:18307374-Humans,
pubmed-meshheading:18307374-Male,
pubmed-meshheading:18307374-Middle Aged,
pubmed-meshheading:18307374-Models, Biological,
pubmed-meshheading:18307374-Morpholines,
pubmed-meshheading:18307374-Nonlinear Dynamics,
pubmed-meshheading:18307374-Prothrombin Time,
pubmed-meshheading:18307374-Sex Factors,
pubmed-meshheading:18307374-Thiophenes,
pubmed-meshheading:18307374-Time Factors,
pubmed-meshheading:18307374-Tissue Distribution,
pubmed-meshheading:18307374-Venous Thromboembolism
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
|
|
pubmed:affiliation |
Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany. wolfgang.mueck@bayerhealthcare.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
